Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Company History

<< Previous

Bullboard Posts

Next >>

Comment by Walterthedogon Dec 29, 2020 10:22pm

193 Views

Post# 32194786

RE:Company History

Hey some of the wording in NRs concerning the recovering of the trial data has me thinking they are legally obligated to be unable to look at it until 3rd party has analyzed? Not sure if this is the case to protect the integrity of the trial or if they are able to look at it. It would just really suck to get blindsided by worse than expected data after all this time. Any info is appreciated.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec